Table 5:
MiTF-translocation histology.
| Agent (trial, year) | Phase | N per group | Primary endpoint | ORR, % (95% CI) | mPFS, months (95% CI) |
OS, months (95% CI) |
|---|---|---|---|---|---|---|
| Sunitinib vs. everolimus (ESPEN, 2016)(18) |
II | 3 Sunitinib 4 Everolimus |
PFS | NA NA |
6.1 (6.0–8.8) 3.0 (1.3–NA) |
16.2 (8.8–NA) 8.1 (5.5–23) |
| Axitinib (2018)(23) | II | 7 | PFS | NA | 11.1 (7.6–14.6) | 16.9 |
ORR: overall response rate, mPFS: median progression-free survival, OS: overall survival, NA: not assessed.